- ISIN
- US74276L1052
- CUSIP
- 74276L105
- Sector
- Healthcare
- Industry
- Medical Devices
- IPO Date
- Sep 15, 2021
Highlights
- Market Cap
- $1.05B
- Enterprise Value
- $852.19M
- EPS (TTM)
- -$2.76
- Total Revenue (TTM)
- $322.02M
- Gross Profit (TTM)
- $206.01M
- EBITDA (TTM)
- -$90.33M
- Year Range
- $16.67 - $47.97
- Target Price
- $47.00
- ROA (TTM)
- -21.04%
- ROE (TTM)
- -29.47%
- Avg. Volume (1M)
- 2M
- Avg. Volume Value (1M)
- $29.61M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PRCT Performance Chart
PROCEPT BioRobotics Corporation (PRCT) is down 41.6% since the beginning of the year. At $18 per share, PRCT is trading 61.7% below its 52-week high of $48.
Loading charts...
Compare this symbol against anything
Returns By Period
PROCEPT BioRobotics Corporation (PRCT) has returned -41.58% so far this year and -63.21% over the past 12 months.
PROCEPT BioRobotics Corporation
- 1D
- -1.29%
- 1M
- -12.60%
- 6M
- -36.93%
- YTD
- -41.58%
- 1Y
- -63.21%
- 3Y*
- -19.10%
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -12.36%
Benchmark (S&P 500 Index)
- 1D
- 1.48%
- 1M
- 1.57%
- 6M
- 8.95%
- YTD
- 11.03%
- 1Y
- 21.84%
- 3Y*
- 19.28%
- 5Y*
- 11.54%
- 10Y*
- 13.29%
- ALL TIME*
- 8.11%
PRCT Monthly Returns History
Based on dividend-adjusted daily data since Sep 15, 2021, PRCT's average daily return is +0.03%, while the average monthly return is -0.03%.
Historically, 47% of months were positive and 53% were negative. The best month was Mar 2022 with a return of +40.1%, while the worst month was Jan 2022 at -25.9%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 9 months.
On a daily basis, PRCT closed higher 48% of trading days. The best single day was Oct 28, 2024 with a return of +32.3%, while the worst single day was Apr 27, 2023 at -25.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.95% | -21.65% | 10.22% | -3.88% | 9.53% | -14.24% | -17.54% | -1.29% | -41.58% | ||||
| 2025 | -9.96% | -11.26% | -9.45% | -7.35% | 7.45% | -0.69% | -15.78% | -17.19% | -11.15% | -4.65% | -6.91% | -0.69% | -60.93% |
| 2024 | 10.47% | 4.41% | 2.23% | 7.20% | 25.33% | -8.00% | 3.65% | 24.76% | 1.42% | 12.33% | 6.21% | -15.77% | 92.13% |
| 2023 | -6.38% | -3.70% | -24.17% | 7.01% | 10.07% | 5.68% | -2.57% | -0.96% | -3.81% | -18.35% | 38.37% | 13.06% | 0.89% |
| 2022 | -25.87% | 34.74% | 40.07% | 1.63% | 10.01% | -16.44% | 17.16% | 5.69% | 2.42% | 9.58% | -5.57% | -3.17% | 66.09% |
| 2021 | 9.00% | 12.01% | -23.64% | -23.35% | -28.54% |
Benchmark Metrics
PROCEPT BioRobotics Corporation has an annualized alpha of -7.36%, beta of 1.24, and R2 of 0.11 versus S&P 500 Index. Calculated based on daily prices since September 15, 2021.
- This stock participated in 142.46% of S&P 500 Index downside but only 46.38% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.11 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -7.36%
- Beta
- 1.24
- R²
- 0.11
- Upside Capture
- 46.38%
- Downside Capture
- 142.46%
Return for Risk
Risk / Return Rank
PRCT ranks 5 for risk / return — above 5% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for PROCEPT BioRobotics Corporation (PRCT) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PRCT | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.71 | ||
| Sortino ratioReturn per unit of downside risk | -4.09 | ||
| Omega ratioGain probability vs. loss probability | 0.81 | 1.31 | -0.50 |
| Calmar ratioReturn relative to maximum drawdown | -0.95 | 2.41 | -3.37 |
| Martin ratioReturn relative to average drawdown | -1.51 | 10.22 | -11.73 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the PROCEPT BioRobotics Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the PROCEPT BioRobotics Corporation was 83.22%, occurring on Jul 24, 2026. The portfolio has not yet recovered.
The current PROCEPT BioRobotics Corporation drawdown is 81.52%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-83.22%Jul 2026 | 1y 7mo | — | 1y 8moDec 2024 - now | — |
-63.51%Jan 2022 | 3mo 15d | 7mo 14d | 10mo 29dOct 2021 - Sep 2022 | Bear market2022 |
-50.86%Oct 2023 | 1y 1mo | 4mo | 1y 5moSep 2022 - Feb 2024 | — |
-21.37%Oct 2024 | 1mo 1d | 4d | 1mo 5dSep 2024 - Oct 2024 | — |
-20.95%Aug 2024 | 18d | 16d | 1mo 4dJul 2024 - Aug 2024 | — |
Drawdown Indicators
| PRCT | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.22% | -56.78% | -26.44% |
Max Drawdown (1Y)Largest decline over 1 year | -66.35% | -9.10% | -57.25% |
Max Drawdown (3Y)Largest decline over 3 years | -83.22% | -18.90% | -64.32% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -81.52% | -0.12% | -81.40% |
Average DrawdownAverage peak-to-trough decline | -33.21% | -10.70% | -22.51% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 42.39% | 2.14% | +40.25% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of PROCEPT BioRobotics Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how PROCEPT BioRobotics Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PRCT relative to other companies in the Medical Devices industry. Currently, PRCT has a P/S ratio of 2.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PRCT
Add PROCEPT BioRobotics Corporation to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PRCT